2 The development of and approval of new antihyperglycemic medications has favored the use of different pharmacological families with remarkable properties for the management of additional comorbidities such as renal disease, cardiovascular disease, and non-alcoholic fatty liver disease, that are highly prevalent in this subset
Understanding these differences helps optimize protocol selection for GERD specifically
REDEFINE-1 (NEJM 2024, n=3417, 68 weeks): CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) 22.7% weight loss (ozempic 2.4 mg 16.1%)
Joint pain and osteoarthritis The TRIUMPH-4 trial produced an unexpected but welcome finding regarding joint health
At TOSM, we take a whole-body approachso if a patient shows signs of gut-related symptoms impacting performance or recovery, we may consider this added benefit when recommending peptides
doi:10.1007/s10517-024-06035-w